Bristol Myers Squibb
BMY NYSE· Pharmaceuticals
Last close · Oct 26, 2026
$61.61
KIRA · Stoqly’s AI analyst, in plain words
- Bristol Myers Squibb had $48.2B of revenue in fiscal 2025, down 0.2% on the year before. Over five years, revenue changed +2.5% a year on average.
- Bristol Myers Squibb made $7.1B of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 3.0% a year.
- Free cash flow was $12.8B in fiscal 2025, 26.7% of revenue.
- Bristol Myers Squibb returned $5.0B to shareholders in fiscal 2025, 39% of free cash flow. The diluted share count rose 0.6%.
- Bristol Myers Squibb owes $36.4B more than it holds in cash, about 2.4 years of operating profit.
Market cap
$126.2B
P/E
13.6x
Revenue
$48.2B
Net income
$7.1B
Free cash flow
$12.8B
Operating margin
—
Bristol Myers Squibb in 30 seconds · fiscal 2025
Are sales growing?
−0.2%
No. Sales fell 0.2% last year.
Does it make a profit?
14.6%
Yes. It keeps 14.6% of every sale as profit.
Does profit turn into cash?
26.7%
Yes. 26.7% of sales ends up as free cash.
Is debt under control?
2.4x
Keep an eye on it. Repaying its debt would take 2.4 years of operating profit.
How healthy are the accounts?
8 / 9
Solid. It passes 8 of 9 health tests.
How is the share priced?
13.6x
One share costs 13.6 times its yearly profit per share. Typical for its sector: 28.4x.
What Bristol Myers Squibb does
Bristol Myers Squibb discovers, develops, makes and sells prescription medicines for serious diseases. It focuses on cancer, blood disorders, immune diseases, heart disease and neuroscience. It reports a single segment. It sells mainly to wholesalers, distributors and specialty pharmacies, and to a lesser extent to retailers, hospitals, clinics, government agencies and patients directly. Its marketed medicines include Opdivo and Yervoy, which are cancer immunotherapies, Orencia for rheumatoid arthritis, Reblozyl for anemia, Breyanzi and Abecma, which are CAR-T cell therapies (treatments made from a patient's own immune cells), Camzyos for a heart condition, Zeposia and Sotyktu for immune conditions, Krazati for lung and colon cancers, and Cobenfy for schizophrenia. The United States made up 69% of its revenues in 2025 and international markets 29%. The company says it competes with other research-based drug companies, smaller research firms and makers of generic drugs.
Biggest risks, in its own words
- Pricing pressure and other limits on drug prices in the U.S. and abroad.
- Losing market exclusivity for a product sooner than expected, and facing lower-priced generics.
- Delays or setbacks in developing and commercializing new products to replace revenue from older ones.
- Depending on a few key products for most of its revenue, cash flow and earnings.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 11, 2026
- Legal name
- BRISTOL-MYERS SQUIBB COMPANY
- CIK
- 0000014272
Bristol Myers Squibb · BMY
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $46.4B | $46.2B | $45.0B | $48.3B | $48.2B |
| Revenue growth | 9.1% | −0.5% | −2.5% | 7.3% | −0.2% |
| Gross margin | 78.6% | 78.0% | 76.2% | 71.1% | 71.1% |
| Net income | $7.0B | $6.3B | $8.0B | −$8.9B | $7.1B |
| Net margin | 15.1% | 13.7% | 17.8% | −18.5% | 14.6% |
| Diluted EPS | $3.12 | $2.95 | $3.86 | −$4.41 | $3.46 |
| Cash | |||||
| Cash from operations | $16.2B | $13.1B | $13.9B | $15.2B | $14.2B |
| Capital expenditure | $973M | $1.1B | $1.2B | $1.2B | $1.3B |
| Free cash flow | $15.2B | $11.9B | $12.7B | $13.9B | $12.8B |
| FCF margin | 32.8% | 25.9% | 28.1% | 28.9% | 26.7% |
| Dividends paid | $4.4B | $4.6B | $4.7B | $4.9B | $5.0B |
| Share buybacks | $6.3B | $8.0B | $5.2B | $0.0M | $0.0M |
| Share count change | −0.6% | −4.4% | −3.2% | −2.5% | 0.6% |
| Debt and strength | |||||
| Cash and short-term investments | $17.0B | $9.3B | $12.3B | $10.9B | $10.7B |
| Debt incl. finance leases | $49.3B | $43.2B | $42.6B | $51.5B | $47.1B |
| Shareholders' equity | $35.9B | $31.1B | $29.4B | $16.3B | $18.5B |
| Net debt / EBITDA | 1.6x | 1.8x | 1.6x | 12.8x | 2.4x |
| Current ratio | 1.5x | 1.3x | 1.4x | 1.3x | 1.3x |
| Interest coverage | 7.1x | 7.3x | 8.2x | −3.3x | 5.9x |
| Returns and quality | |||||
| Return on capital | 11.4% | 11.0% | 14.7% | −8.7% | 15.2% |
| Return on equity | 19.0% | 18.9% | 26.5% | −39.1% | 40.5% |
| Piotroski F-score | 7 | 6 | 7 | 4 | 8 |
| Altman Z'' | 2.5 | 2.3 | 2.8 | 0.7 | 2.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$2.3M
3 insiders
Of sales under plans
81%
$1.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Bristol Myers Squibb · BMY
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb BMY | $126.2B | −0.2% | — | 26.7% | 15.2% | 13.6x | 8 |
| AstraZeneca AZN | $268.8B | 8.6% | 23.4% | 20.0% | 16.8% | — | 9 |
| Pfizer PFE | $169.8B | −1.7% | — | 14.5% | 7.3% | 39.2x | 6 |
| Merck MRK | $347.3B | 1.3% | — | 19.0% | 24.8% | 111.6x | 4 |
| Eli Lilly LLY | $1.14T | 44.7% | — | 13.8% | 40.8% | 42.9x | 8 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $61.61 a share, the company is worth $126.2B: 13.6 times its earnings of the last four quarters.
Bristol Myers Squibb grew sales faster than 1 of its 4 similar companies. Its P/E is higher than 0 of 3.
Source: SEC EDGAR XBRL filings (CIK 0000014272). Data updated October 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.